| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1623.1B | ¥1675.9B | -3.2% |
| Operating Income | ¥141.8B | ¥142.3B | -0.4% |
| Ordinary Income | ¥150.7B | ¥159.9B | -5.8% |
| Net Income | ¥127.2B | ¥124.0B | +2.5% |
| ROE | 5.9% | 5.8% | - |
Fiscal Year 2025 consolidated results: Revenue of 162.3B yen (YoY -3.2%), Operating Income of 14.2B yen (YoY -0.4%), Ordinary Income of 15.1B yen (YoY -5.8%), Net Income of 12.7B yen (YoY +2.5%). The company maintained operating profitability near prior year levels despite revenue decline, with gross profit margin sustained at 29.0%. Net income increased 2.5% supported by a 5.3B yen gain on sale of investment securities, offsetting the decline in ordinary income. Operating cash flow of 22.3B yen exceeded net income by 1.75x, demonstrating strong cash conversion quality. However, free cash flow turned negative at -7.3B yen due to significant capital investment of 28.0B yen, representing 2.40x depreciation expense, indicating an active growth investment phase. The company executed shareholder returns totaling 13.9B yen through dividends of 6.9B yen and share buybacks of 7.0B yen. Financial position remains robust with equity ratio of 74.7%, current ratio of 233.4%, and net debt-to-equity ratio of 0.05x.
Revenue decreased 5.3B yen to 162.3B yen, down 3.2% YoY, primarily driven by decline in Commodity Chemicals segment sales from 79.1B yen to 71.8B yen (-9.3%), representing a 7.4B yen revenue headwind. By geography, domestic sales declined 5.8B yen to 132.9B yen while Asia increased 0.5B yen to 20.0B yen and North America grew 0.4B yen to 5.5B yen, indicating the revenue decline was concentrated in the domestic market. The Commodity Chemicals segment's performance reflects weaker demand conditions in caustic soda, caustic potash, and acrylic monomer products. Polymer and Oligomer segment sales increased 1.0B yen to 36.2B yen (+2.8%), providing partial offset through acrylic polymer and superabsorbent polymer demand. Operating income decreased marginally by 0.1B yen to 14.2B yen (-0.4%), demonstrating cost discipline despite revenue headwinds. The operating margin improved slightly to 8.7% from 8.5%, indicating effective cost management. Gross profit margin maintained at 29.0% suggests stable product pricing and mix. Selling, general and administrative expenses increased 1.9B yen to 33.0B yen, with the SG&A ratio rising to 20.3% from 18.5%, reflecting operating deleverage on lower sales volumes. Ordinary income declined 0.9B yen to 15.1B yen (-5.8%), underperforming operating income due to net non-operating expenses of 0.9B yen. The gap between ordinary income of 15.1B yen and net income of 12.7B yen reflects extraordinary items: extraordinary gains of 5.4B yen (primarily 5.3B yen from investment securities sales) offset by extraordinary losses of 0.6B yen (including 0.4B yen impairment loss in Commodity Chemicals) and tax expenses. Excluding the one-time investment securities gain, recurring earnings quality would be weaker. The company recorded impairment losses totaling 0.4B yen in the Commodity Chemicals segment during the period, compared to 1.4B yen in the prior year, indicating continued asset rationalization efforts. This represents a revenue down, profit flat pattern, where top-line pressure was absorbed through margin maintenance and supported by non-recurring gains at the net income level.
Commodity Chemicals represents the largest segment at 71.8B yen revenue (44.9% of total segment sales) but declined 9.3% YoY from 79.1B yen, with operating income of 8.8B yen declining 2.8% from 9.1B yen. The segment margin of 12.2% declined slightly from 12.8%, reflecting volume and mix pressure in caustic soda and acrylic monomer markets. Polymer and Oligomer generated 37.7B yen revenue (+2.8% YoY) with operating income of 3.0B yen (-20.1% YoY), showing margin compression to 8.0% from 10.7% despite revenue growth, indicating cost or competitive pressures. Plastics segment revenue increased 1.7% to 29.0B yen with operating income of 2.8B yen (+56.4% YoY), achieving the highest profitability improvement with margin expansion to 9.5% from 6.4%, driven by operational efficiency gains. Adhesive Material segment sales increased 2.0% to 13.7B yen but operating income declined sharply to 0.3B yen from 0.4B yen (-21.0% YoY), with margin deteriorating to 2.4% from 3.1%, indicating pricing or cost challenges in instant adhesive and functional adhesive products. Performance Chemicals segment revenue increased marginally to 10.7B yen (+0.3% YoY) with operating income of 1.2B yen (-7.7% YoY), margin declining to 11.0% from 12.5%. The core business Commodity Chemicals faces structural headwinds requiring attention, while Plastics demonstrates strong operational momentum. Material margin differences exist, with Commodity Chemicals at 12.2%, Performance Chemicals at 11.0%, and Adhesive Material at only 2.4%, reflecting divergent competitive dynamics and value positioning across segments.
[Profitability] ROE of 5.9% declined from 5.8% prior year, remaining below the company's historical average and reflecting limited return on equity despite net income growth supported by one-time gains. Operating margin of 8.7% improved 0.2 percentage points from 8.5% YoY, demonstrating cost discipline offsetting volume pressure. Net profit margin of 7.8% improved from 7.4% YoY, though this includes the favorable impact of 5.3B yen investment securities sale gain representing 3.3% of revenue. Gross profit margin maintained at 29.0% indicates stable pricing power and product mix despite market headwinds. [Cash Quality] Cash and deposits of 24.5B yen decreased from 30.1B yen prior year, with cash coverage of short-term liabilities at 3.57x indicating strong liquidity despite the decline. Operating cash flow of 22.3B yen represents 1.75x net income, confirming strong cash earnings quality. Operating CF to EBITDA ratio of 0.86x demonstrates solid cash conversion from operating activities. [Investment Efficiency] Total asset turnover of 0.56x declined from 0.60x, reflecting asset growth outpacing revenue growth due to significant capital investment. Fixed asset turnover of 1.26x compares to prior 1.30x, indicating capacity utilization pressure. Days sales outstanding of 85 days increased from 78 days, signaling slower accounts receivable collection and working capital pressure. Days inventory outstanding of 81 days versus 73 days prior year indicates inventory accumulation, warranting attention for potential obsolescence risk. [Financial Health] Equity ratio of 74.7% improved from 76.9%, maintaining strong capitalization. Current ratio of 233.4% versus prior 254.5% remains robust despite decline. Debt-to-equity ratio of 0.34x increased from 0.30x, though remains conservative with net debt-to-equity at only 0.05x given substantial cash holdings.
Operating cash flow of 22.3B yen represents 1.75x net income of 12.7B yen, confirming cash-backed earnings quality with strong conversion from accrual-based profits to cash. The operating CF to EBITDA ratio of 0.86x indicates solid operating cash generation relative to earnings before interest, taxes, depreciation and amortization. Investing cash flow of -29.6B yen was dominated by capital expenditures of 28.0B yen, representing 2.40x depreciation expense of 11.7B yen, signaling an intensive growth and capacity expansion investment phase. Construction in progress of 26.0B yen on the balance sheet corroborates ongoing major projects. Free cash flow of -7.3B yen reflects the substantial investment outflow exceeding operating cash generation, a typical pattern during strategic capex cycles. Financing cash flow of -4.5B yen comprised dividend payments of 6.9B yen and share buybacks of 7.0B yen totaling 13.9B yen in shareholder returns, partially offset by debt financing activities. Cash and deposits decreased 5.6B yen from 30.1B yen to 24.5B yen year-over-year, primarily reflecting the free cash flow deficit and financing outflows. Working capital movements show accounts receivable increased 1.8B yen indicating extended collection cycles with DSO rising to 85 days from 78 days, while inventories increased 2.5B yen reflecting accumulation with DIO rising to 81 days from 73 days. Short-term debt coverage by cash stands at 3.57x, indicating adequate liquidity buffers despite cash utilization. The cash conversion cycle deterioration driven by receivables and inventory growth warrants operational attention to optimize working capital efficiency and support future cash generation capacity.
Ordinary income of 15.1B yen versus operating income of 14.2B yen indicates non-operating net contribution of approximately 0.9B yen, representing 0.6% of revenue. This modest level suggests limited dependency on non-operating activities for core earnings. However, the progression from ordinary income of 15.1B yen to net income of 12.7B yen involves significant extraordinary items that materially impact earnings quality assessment. Extraordinary gains totaled 5.4B yen, consisting primarily of 5.3B yen in investment securities sale gains, representing a substantial 3.3% of revenue and 41.7% of net income. Extraordinary losses of 0.6B yen included 0.4B yen in impairment losses within the Commodity Chemicals segment. The net extraordinary gain of 4.8B yen before tax materially elevated reported net income, indicating that recurring earnings power is notably lower than the reported 12.7B yen. Excluding the 5.3B yen securities gain and adjusting for associated tax effects, normalized net income would approximate 9B yen, representing a decline from prior year levels. Operating cash flow of 22.3B yen significantly exceeds reported net income of 12.7B yen by 1.75x, demonstrating healthy cash conversion from operating activities and confirming that operating earnings generate strong cash backing. The cash quality metric validates operating profit reliability despite one-time gains inflating net income. Interest expense of 0.2B yen remains minimal relative to operating income, confirming low financial risk. The earnings profile reveals solid operating performance with strong cash generation, but reported net income growth of 2.5% is entirely attributable to non-recurring investment gains rather than operational improvement, requiring investors to normalize for sustainable earnings assessment.
Full-year guidance projects revenue of 167.0B yen, operating income of 14.5B yen, ordinary income of 15.1B yen, and net income of 11.5B yen. Actual full-year results achieved revenue of 162.3B yen (97.2% of forecast), operating income of 14.2B yen (97.9% of forecast), ordinary income of 15.1B yen (100.0% of forecast), and net income of 12.7B yen (110.4% of forecast). Revenue underperformed guidance by 4.7B yen primarily due to weaker-than-expected Commodity Chemicals demand, while operating income fell slightly short by 0.3B yen. Ordinary income met guidance precisely at 15.1B yen. Net income exceeded forecast by 1.2B yen (+10.4%), attributable to the 5.3B yen investment securities gain that was not incorporated in original guidance assumptions. The net income outperformance reflects opportunistic asset monetization rather than operational upside. Year-on-year guidance implies revenue growth of 2.9%, operating income growth of 2.3%, and ordinary income growth of 0.2%, indicating modest recovery expectations. The forecast assumes stabilization in Commodity Chemicals market conditions and continued contribution from higher-margin segments. Dividend forecast of 35 yen per share represents a reduction from actual 60 yen paid in the current year, suggesting more conservative shareholder return expectations aligned with normalized earnings trajectory excluding one-time gains.
Annual dividend of 60 yen per share comprises interim dividend of 30 yen and year-end dividend of 30 yen, representing an increase from prior year levels and demonstrating commitment to shareholder returns despite revenue headwinds. Based on net income of 12.7B yen and total dividend payments of 6.9B yen, the dividend payout ratio calculates to 54.3%, which falls within a sustainable range below 60% threshold. However, this includes the non-recurring 5.3B yen investment securities gain; normalizing net income to exclude this one-time item would result in a significantly higher payout ratio approximating 75-80%, indicating the dividend level may not be fully supported by recurring earnings. Share buyback execution totaled 7.0B yen during the fiscal year, demonstrating active capital allocation to enhance shareholder value. Combined dividends of 6.9B yen and buybacks of 7.0B yen result in total shareholder returns of 13.9B yen, yielding a total return ratio of 109.4% relative to reported net income of 12.7B yen. This exceeds 100% return ratio when measured against reported earnings, though appears more sustainable when considering the 5.3B yen one-time gain as available for distribution. Free cash flow of -7.3B yen turned negative due to intensive capital investment, meaning total shareholder returns of 13.9B yen were funded through operating cash flow and existing cash reserves rather than free cash generation. Operating cash flow of 22.3B yen provided 1.60x coverage of total returns, confirming operational cash generation capacity supports shareholder distributions. The forward dividend guidance of 35 yen per share represents a 41.7% reduction from current 60 yen level, aligning with expectations for normalized earnings excluding one-time gains and indicating a more sustainable payout policy going forward.
Market demand volatility in Commodity Chemicals: The core Commodity Chemicals segment generating 44.9% of revenue experienced 9.3% sales decline to 71.8B yen, reflecting cyclical exposure to caustic soda, acrylic monomers, and industrial gas markets. This segment recorded 0.4B yen in impairment losses during the period following 1.4B yen prior year, indicating ongoing asset rationalization amid structural demand challenges. Continued weakness in chemical industry end-markets, particularly domestic manufacturing, could further pressure revenues and margins. The segment's 12.2% operating margin declined from 12.8%, and further deterioration would materially impact group profitability given the segment's scale.
Working capital deterioration and liquidity pressure: Days sales outstanding extended to 85 days from 78 days (+9.0%) while days inventory outstanding increased to 81 days from 73 days (+11.0%), resulting in cash conversion cycle degradation. Accounts receivable notes (electronically recorded monetary claims) of 11.6B yen represent concentrated credit exposure. Inventory accumulation of 2.5B yen YoY raises obsolescence risk if demand fails to materialize. Combined with intensive capital investment of 28.0B yen creating negative free cash flow of 7.3B yen, continued working capital expansion could constrain financial flexibility and require additional external financing despite current strong liquidity position.
Investment execution and return realization risk: Capital expenditures of 28.0B yen represent 2.40x depreciation and 1.73x operating income, with construction in progress at 26.0B yen indicating major projects underway. The investment intensity aims to enhance capacity and high-value product capabilities, but return realization depends on market demand recovery, successful commercialization of new products, and operational execution. Delay in investment payback or lower-than-expected returns would pressure ROE (currently 5.9%), operating cash flow generation, and dividend sustainability. Additionally, intangible assets surged 3.1B yen to 4.7B yen (+183.5%), requiring monitoring for impairment risk if associated projects underperform.
[Industry Position] (Reference - Proprietary Analysis) The company's operating margin of 8.7% compares to chemical industry dynamics where larger diversified players typically achieve 10-15% operating margins while commodity-focused producers face 5-10% margin compression during cyclical downturns. The company's positioning reflects mid-tier profitability within specialty and commodity chemicals, with performance constrained by Commodity Chemicals exposure but supported by higher-margin Performance Chemicals (11.0% margin) and Plastics (9.5% margin) segments. ROE of 5.9% appears modest relative to chemical industry median ranges of 8-12% for specialty chemical producers, indicating efficiency improvement opportunities through asset turnover enhancement and margin expansion. The company's equity ratio of 74.7% significantly exceeds typical industry leverage profiles where chemical manufacturers maintain 50-60% equity ratios, reflecting conservative financial management but potentially underutilized financial capacity. Dividend payout ratio of 54.3% aligns with industry practices of 40-60% for mature chemical companies, though the normalized payout excluding one-time gains would exceed industry norms. The company's revenue growth of -3.2% underperforms broader specialty chemical sector growth trends of 2-5% in stable periods, highlighting competitive positioning challenges and domestic market dependency. Historical comparison shows the company's operating margin of 8.7% improved from 8.5% prior year but remains below its own multi-year performance, while net profit margin of 7.8% benefits from one-time items. The intensive capital investment phase with CapEx/depreciation of 2.40x positions for future competitiveness but near-term returns sustainability depends on successful project execution and market recovery.
Operating fundamentals demonstrate resilience with maintained gross margins of 29.0% and controlled operating expenses despite 3.2% revenue decline, indicating effective cost management and pricing discipline across the portfolio. However, core earnings power excluding the 5.3B yen investment securities gain reveals underlying profitability pressure, with ordinary income declining 5.8% YoY and normalized net income below reported levels, signaling the need for revenue growth recovery to sustain historical profitability trends.
Strategic capital allocation reflects significant investment commitment with 28.0B yen CapEx representing 2.40x depreciation, positioning for capacity expansion and high-value product development, particularly evident in the 3.1B yen intangible asset increase (+183.5%) suggesting technology and capability investments. The 26.0B yen construction in progress indicates multi-year project execution phase, with return realization critical to validating the investment thesis and improving ROE from current 5.9% which lags industry benchmarks.
Financial flexibility remains robust with 74.7% equity ratio, minimal net debt-to-equity of 0.05x, and operating cash flow of 22.3B yen covering shareholder returns of 13.9B yen by 1.60x, confirming capacity to sustain capital allocation to both growth investment and shareholder distributions. However, working capital deterioration with DSO extending to 85 days and DIO increasing to 81 days represents an execution risk requiring operational focus to optimize cash conversion efficiency and prevent further liquidity consumption during the investment phase.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.